Both BCL2 immunoexpression and EZH2/BCL2 co-expression were more frequent in HGBCL–DH/TH when compared to DLBCL-NOS (100% vs. 54%, p = 0.025 and 50% vs. 10%, p = 0.004, respectively). Here, BCL2 is linked to diffuse large B-cell lymphoma.